WALTHAM, Mass.– PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that Michel Vounatsos has been elected to its board of directors, effective March 1, 2020.

“I am excited to welcome Michel to PerkinElmer’s board, as he brings us deep knowledge and broad-based experience in key end markets,” said Alexis Michas, non-executive chairman of the board of PerkinElmer. “Adding Michel’s comprehensive global leadership expertise gained from his decades of executive service, along with his background in medicine and business, will greatly benefit the development and execution of the strategy to drive PerkinElmer’s next phase of growth.”

Mr. Vounatsos currently serves as chief executive officer of Biogen, as well as a member of its board of directors. He joined Biogen in 2016 as executive vice president, chief commercial officer after a 20-year career at Merck. While at Merck, he held leadership positions of increasing responsibility in Europe, China, and the U.S. He served as president, Primary Care Customer Business Line and Merck Customer Centricity leading Merck’s global primary care business unit, a role which encompassed Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups. Mr. Vounatsos also developed and instituted a strategic framework for enhancing Merck’s relationships with key constituents, including providers, payers and retailers and governmental bodies throughout the world. Earlier in his career, he held management positions at Ciba-Geigy.

Mr. Vounatsos received his C.S.C.T. certificate in Medicine from the Université Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.

About PerkinElmer, Inc.

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.